Australia Drug Addiction Statistics 2026 | Ice, Opioids & Key Crisis Facts

Drug Addiction in Australia 2026

Australia drug addiction statistics for 2026 are drawn from some of the most rigorously maintained government surveillance systems of any country in the world, led by the Australian Institute of Health and Welfare (AIHW) and its flagship publication “Alcohol, Tobacco & Other Drugs in Australia”, which consolidates data from the National Drug Strategy Household Survey, the Illicit Drug Reporting System (IDRS), the Ecstasy and Related Drugs Reporting System (EDRS), the National Wastewater Drug Monitoring Program, and the national treatment services minimum dataset. The picture these sources collectively reveal is of a country where illicit drug use contributed 2.9% to the total burden of disease in 2024, where 1,948 Australians died from drug-induced causes in 2024, and where an enormous treatment system — delivering over 127,800 specialist alcohol and other drug treatment episodes in 2024–25 — remains stretched by demand that has proved difficult to meaningfully reduce across multiple drug categories simultaneously.

Australia’s drug addiction landscape in 2026 is defined by three intersecting crises. The first is the persistent and long-term challenge posed by methamphetamine (ice), which continues to dominate treatment demand and hospitalisation data despite a measured decline in recent use prevalence since the mid-2000s peak. The second is the ongoing opioid crisis, where pharmaceutical opioids have increasingly supplemented or replaced heroin as the primary driver of overdose death, with opioids now present in more than half of all drug-induced deaths. The third is the sheer breadth of cannabis use, where 2.5 million Australians — more than 10% of the total population aged 14 and over — used cannabis in the previous 12 months as of the most recent National Drug Strategy Household Survey, making Australia one of the highest-use countries on earth. This article compiles the latest, most current verified statistics from AIHW and associated government sources on Australia’s drug addiction reality in 2026.

Interesting Facts About Drug Addiction in Australia 2026

Source: AIHW (Australian Institute of Health and Welfare), “Alcohol, tobacco & other drugs in Australia” (2026 edition, content current as at 24 February 2026, accessed 25 June 2026); AIHW, “Alcohol and other drug treatment services in Australia: early insights” (2026, accessed 16 April 2026); AIHW analysis of ABS National Mortality Database (NMD), 2024; AIHW 2022–2023 National Drug Strategy Household Survey (NDSHS) summary; AIHW Illicit Drug Reporting System (IDRS) 2025 (Sutherland et al. 2025b); AIHW Ecstasy and Related Drugs Reporting System (EDRS) 2025 (Sutherland et al. 2025a); Gadsden et al. (2024), Updated social and economic costs of alcohol, tobacco, and drug use in Australia, 2022/23, The George Institute for Global Health

The facts table above reveals a drug addiction landscape that continues to exact an enormous human and financial toll on Australia, even as certain trends — particularly the long-term decline in methamphetamine prevalence and the falling per-100,000 drug death rate — offer measured signs of progress. The 1,948 drug-induced deaths recorded in 2024 represent a figure the AIHW explicitly flags as preliminary, noting that “estimates for 2023 and 2024 are expected to rise following standard revision processes,” meaning the final confirmed total for 2024 will likely be higher than the current AIHW figure. The 7.1 deaths per 100,000 population rate, while lower than the 8.2 per 100,000 recorded in 2017, should be interpreted with this revision caveat in mind.

The 127,800-plus specialist treatment clients in 2024–25 represents a treatment system operating at substantial scale, but the AIHW and independent researchers have consistently noted that this figure captures only those who actually access publicly funded services — not the broader population in need. AIHW feature analysis of treatment services mortality data has found that people receiving treatment for heroin and pharmaceutical drugs have a higher mortality rate than people receiving treatment for other substances such as alcohol, amphetamines, or cannabis, a finding that directly informs the policy emphasis on improving retention and continuity of care specifically for opioid-dependent individuals. The 2.9% burden of disease contribution from illicit drug use in 2024 places drug addiction on a par with several major chronic diseases in terms of its impact on years of healthy life lost across the Australian population.

Ice (Methamphetamine) Statistics in Australia 2026

Methamphetamine — Key Trend Indicators (AIHW/EDRS/NDSHS Data)
──────────────────────────────────────────────────────────────────────
EDRS use rate 2003 (peak)   │████████████████████████████████████████  84%
EDRS use rate 2025          │████████████░░░░░░░░░░░░░░░░░░░░░░░░░░░░  29%
Treatment episodes 2019-20  │████████████████████████████████████████  60,987 (peak)
Treatment episodes 2024-25  │████████████████████████████████░░░░░░░░  50,900
Hospitalisation rate 2023-24│████████████████████████████████████████  56 per 100,000 (peak)
NDSHS recent use 2022-23    │████░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░  1.0% of population
                            └──────────────────────────────────────────
                               (Source: AIHW EDRS 2025; AIHW NDSHS 2022-23;
                               AIHW Treatment Services early insights 2026)

Source: AIHW, “Alcohol, tobacco & other drugs in Australia” — Amphetamines and other stimulants section (2026, accessed 17 June 2026); AIHW EDRS 2025 (Sutherland et al. 2025a); AIHW NDSHS 2022–23; AIHW “Alcohol and other drug treatment services in Australia: early insights” (2026)

Methamphetamine (ice) remains Australia’s most treatment-intensive illicit drug, accounting for 24% of all specialist drug treatment episodes in 2024–25 — a figure second only to alcohol in the treatment hierarchy. The long-term trend story is mixed: on one hand, the headline recent-use prevalence of 1.0% of the population (around 200,000 people) is significantly lower than peak-period figures, and EDRS data confirms a dramatic fall from 84% of regular drug users reporting methamphetamine use in 2003 to just 29% in 2025. On the other hand, the methamphetamine hospitalisation rate hit a record high of 56 per 100,000 population in 2023–24, suggesting that while fewer people are using the drug overall, those who are using it are experiencing harm severe enough to require hospital admission at the highest rate ever recorded.

The crystal/ice form of methamphetamine continues to dominate the market, preferred by 43% of recent users compared to 31% for powder/speed — a market composition that reflects the drug’s ongoing shift toward its most potent, most physically damaging form since the early 2010s. The AIHW’s wastewater monitoring data confirms that methylamphetamine is the fourth most commonly detected drug in Australia’s wastewater behind alcohol, nicotine, and cannabis, and that both price and purity have remained relatively stable in recent years — a finding from the Illicit Drug Reporting System that directly challenges the assumption that supply disruption or price increases are significantly deterring use. The National Ice Action Strategy and the broader National Drug Strategy 2017–2026 both specifically target methamphetamine harm reduction, and the 2026 cycle of both frameworks includes provisions for community-level responses, treatment expansion, and workforce training specifically tailored to methamphetamine dependence.

Opioid Addiction & Overdose Statistics in Australia 2026

Opioids in Drug-Induced Deaths & Overdose Data (2024, AIHW/ABS NMD)
──────────────────────────────────────────────────────────────────────
Opioid presence in drug-induced deaths │████████████████████████████  53% (1,025 deaths)
Opioid deaths classified as accidental  │████████████████████████████████████████  80% (819 deaths)
Opioid-only deaths (no co-use)          │Minority — co-involvement with benzos/other drugs common
329,000 opioid patients also dispensed  │benzodiazepines in the previous 30 days (PBS 2024-25)
IDRS non-fatal opioid overdose (2025)   │████████░░░░░░░░░░░░░░░░░░░░░░░░  12% in past 12 months
Heroin treatment episodes (2024-25)     │███░░░░░░░░░░░░░░░░░░░░░░░░░░░░░  ~9,200 (4.3%)
                                          └────────────────────────────────────────────
                                          (Source: AIHW/ABS NMD 2024; AIHW PBS analysis
                                          2024-25; AIHW IDRS 2025; AIHW treatment 2026)

Source: AIHW analysis of ABS National Mortality Database (NMD) 2024 (AIHW 2026b); AIHW analysis of PBS data collection 2024–25 (AIHW 2026); AIHW National Opioid Pharmacotherapy Statistics Annual Data collection (AIHW 2026, accessed 24 June 2026); AIHW IDRS 2025 (Sutherland et al. 2025b); AIHW “Alcohol and other drug treatment services in Australia: early insights” (2026)

The opioid addiction statistics in Australia tell a nuanced story that differs in important respects from the North American opioid crisis narrative. While opioids are present in more than half of all drug-induced deaths in Australia, the pattern is shaped as much by pharmaceutical opioids as by heroin, and the key risk multiplier is co-use with benzodiazepines rather than fentanyl adulteration — the dominant driver of overdose deaths in the United States and Canada. The AIHW’s 2024–25 pharmaceutical data is striking on this point: 329,000 patients who were dispensed opioids also received benzodiazepines within the previous 30 days — a combination that dramatically elevates the risk of fatal respiratory depression. This figure directly underpins Australia’s ongoing regulatory efforts to restrict concurrent prescribing and introduce stricter real-time prescription monitoring.

The falling rate of opioid dispensing via the PBS since 2017–18 is a genuine and measurable policy success, driven by the removal of over-the-counter opioid availability in 2018, the introduction of real-time prescription monitoring, and prescriber education initiatives. However, this success in reducing the supply of opioids has not translated into a proportional reduction in opioid-related harm, partly because people who are already opioid-dependent have shifted toward other sources including illicit heroin, imported fentanyl analogues, and diversion of prescribed opioids from other patients. The AIHW’s IDRS monitoring confirms that 12% of regular opioid users reported a non-fatal overdose in the past 12 months in 2025 — an unchanged rate from 2024 — suggesting that harm reduction initiatives, while preventing worse outcomes, have not yet reduced the underlying frequency of overdose events within the most high-risk using population.

Cannabis Addiction & Use Statistics in Australia 2026

Cannabis Use Indicators — Australia 2022–23 NDSHS (Most Recent National Survey)
──────────────────────────────────────────────────────────────────────────────────
Past 12 months users (population 14+) │████████████████████████████████████████  2.5 million (10.1%)
Daily users (among recent users 2022-23)│████████████████████████░░░░░░░░░░░░░░░░  18%
Annual use increase vs 2019             │More women 18-24 using (27%→35%); men stable
Offered/had opportunity to use (2022-23)│████████████████████████░░░░░░░░░░░░░░░░  25% of population
Treatment episodes 2024-25             │████░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░  30,300 (14%)
Social cost (projected 2022-23)        │████████████████████████████████████████  $5.2 billion
                                          └────────────────────────────────────────────────────
                                          (Source: AIHW NDSHS 2022-23; AIHW 2026;
                                          Gadsden et al. 2024, George Institute)

Source: AIHW, “Alcohol, tobacco & other drugs in Australia” — Cannabis section (2026, accessed 28 April 2026); AIHW NDSHS 2022–23; AIHW “Alcohol and other drug treatment services in Australia: early insights” (2026); Gadsden et al. (2024), “Updated social and economic costs of alcohol, tobacco, and drug use in Australia, 2022/23,” The George Institute for Global Health

Australia’s cannabis statistics are extraordinary by any international comparison: with 2.5 million people reporting cannabis use in the previous 12 months in 2022–23, representing roughly 10% of the entire population aged 14 and over, the AIHW notes that Australia has “among the highest cannabis use rates in the world” per UNODC comparative data. The increase in daily use from 14% to 18% of recent cannabis users between 2019 and 2022–23 is a specific area of concern, since daily use is far more strongly associated with dependence, mental health harms, and educational and occupational impacts than occasional use. The mental health co-occurrence data is also striking: cannabis users were more than twice as likely to experience anxiety and depression as non-users, and twice as likely to experience high or very high psychological distress — though the AIHW notes this is a correlational relationship, and the causal direction between cannabis use and mental health remains an active area of research.

The $5.2 billion projected social cost of cannabis use in 2022–23, with more than half of that figure ($2.8 billion) attributable to criminal justice costs including imprisonment and community supervision, is a number that features increasingly prominently in public policy discussions about cannabis regulation in Australia. This criminal justice cost structure — where the majority of cannabis’s social cost burden flows from enforcement rather than health — directly informs the ongoing national debate about decriminalisation and regulation, a debate that already produced the ACT’s 2020 decriminalisation of personal cannabis possession and that continues to advance in various state-level policy processes heading into 2026. The Aboriginal and Torres Strait Islander population’s disproportionate representation at 23% of all cannabis treatment clients in 2023–24 — against a national population share of around 3.8% — represents one of the most significant equity dimensions of the cannabis treatment landscape, one that intersects directly with the AIHW’s broader findings about socioeconomic disadvantage and drug-related hospitalisation risk.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE